Celltrion Pharm, Inc.
Financials
Valuation Metrics
Celltrion Pharm, Inc.'s Market Cap is ₩1.9T. At end of 2025 it was ₩2.6T. Ranked #215 of 2,436 in KR market (top 9%), #44 of 1,649 on KOSDAQ (top 3%), #22 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.85T KRW | KR#215/2,436 Sec#22/234 |
| Revenue | 556.00B KRW | KR#571/2,436 Sec#28/234 |
| Net Income | 40.25B KRW | KR#423/2,436 Sec#28/234 |
| Total Assets | 768.81B KRW | KR#554/2,436 Sec#32/234 |
| Net Assets | 434.82B KRW | KR#552/2,436 Sec#33/234 |
| Employees | 920 | KR#275/2,436 Sec#22/234 |
| Value | ||
| P/E | 46.00x | KR#1,339/2,436 Sec#87/234 |
| P/B | 4.26x | KR#2,216/2,436 Sec#183/234 |
| PEG | 2.25x | KR#804/2,436 Sec#53/234 |
| P/S | 3.33x | KR#2,042/2,436 Sec#130/234 |
| EV/EBITDA | 33.25x | KR#1,222/2,436 Sec#84/234 |
| FCF Yield | 3.79% | KR#949/2,436 Sec#55/234 |
| Profitability | ||
| ROE | 9.26% | KR#573/2,436 Sec#35/234 |
| ROA | 5.24% | KR#617/2,436 Sec#48/234 |
| Op. Margin | 10.48% | KR#465/2,436 Sec#43/234 |
| Revenue Growth | 17.42% | KR#694/2,436 Sec#67/234 |
| Earnings Growth | 20.44% | KR#748/2,436 Sec#47/234 |
| Financial Health | ||
| Debt Ratio | 176.81% | KR#1,505/2,436 Sec#172/234 |
| Total Debt | 142.00B KRW | KR#597/2,436 Sec#32/234 |
| FCF | 70.27B KRW | KR#237/2,436 Sec#14/234 |
| Cash | 56.79B KRW | KR#691/2,436 Sec#38/234 |
| Current Ratio | 1.65x | KR#1,193/2,436 Sec#131/234 |
| Net Debt/EBITDA | 1.46x | KR#847/2,436 Sec#59/234 |
| Dividend | ||
| Div. Yield | 0.49% | KR#1,285/2,436 Sec#83/234 |
| Performance | ||
| 1Y Return | -19.31% | KR#1,251/2,436 Sec#102/234 |
| 1M Return | -0.48% | KR#990/2,436 Sec#86/234 |
| From 52W High | -46.74% | KR#1,050/2,436 Sec#83/234 |
| 1Y MDD | -49.80% | KR#923/2,436 Sec#77/234 |
| Trading | ||
| Volume | 112,068 shares | KR#1,026/2,436 Sec#97/234 |
| Foreign Own. | 5.18% | KR#788/2,436 Sec#74/234 |
| Per Share | ||
| EPS | 903 KRW | KR#664/2,436 Sec#46/234 |
| BPS | 9,849 KRW | KR#949/2,436 Sec#66/234 |
Company Info
This specialized pharmaceutical manufacturing and sales company was established in 2000 and listed on KOSDAQ in 2006. It operates KGMP, US cGMP, and EU-GMP certified facilities in Ochang and Jincheon, Chungcheongbuk-do, producing specialized pharmaceuticals and biopharmaceuticals via PFS production lines. The company holds domestic exclusive sales rights for chemical pharmaceuticals like the liver disease treatment Godex, and 12 biopharmaceuticals, including autoimmune disease treatments and anti-cancer drugs developed by its parent company, Celltrion, while actively pursuing pipeline expansion and technological platform innovation.